Microplastic exposure and progression of stomach precancerous changes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will group adults into chronic non-atrophic gastritis, precancerous lesions, and gastric cancer based on endoscopy and/or biopsy findings. Researchers will collect demographic data, Helicobacter pylori status, and a structured questionnaire measuring external microplastic exposure and sources. The analysis will compare exposure scores across the three groups and use statistical models to see if microplastic exposure is an independent risk factor for gastric mucosal carcinogenesis. Patients with recent diagnoses who can complete the questionnaire in person at the study center are eligible, while those with prior other malignancies, major organ failure, recent upper GI surgery, or incomplete data are excluded.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged between 18 and 75 years old, gender is not restricted
* Having a clear diagnosis result within the recent three months and being diagnosed with chronic non - atrophic gastritis, precancerous lesions of gastric cancer, or gastric cancer for the first time
* Have clear Helicobacter pylori (Hp) test results
* Be in normal mental state and able to independently complete the questionnaire survey

Exclusion Criteria:

* Patients with a history of malignant tumors in other parts
* Patients who have previously undergone upper gastrointestinal surgery, chemotherapy, or radiotherapy
* Patients with severe diseases of major organs such as the heart, lungs liver, and kidneys
* Patients who are currently receiving psychological intervention or taking psychiatric drugs
* Pregnant or lactating women
* Patients with severe missing clinical data or questionnaire information
* Refusing to sign the informed consent form

Where it's running

• Xijing Hosipital of Digestive Disease
  Xi'an, Shaanxi, China Recruiting

Study contacts

• Study coordinator: Yongquan Shi
• Email: shiyquan@fmmu.edu.cn
• Phone: 029-84771515

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PF-08098488 in adults with advanced solid tumors

  This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.

  Recruiting at 4 sites Phase 1 Pfizer · Grand Rapids, Michigan and 3 other locations · NCT07903415

• ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients

  This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.

  Recruiting at 2 sites Tam Anh Research Institute · Hanoi, Hanoi and 1 other locations · NCT07808164

• Prevalence and possible role of non-H. pylori Helicobacter species in gastric conditions and cancers

  Researchers will test stomach tissue from people with functional dyspeasia, various gastritis conditions, gastric cancer, and bariatric patients to see if non-H. pylori Helicobacter species are present.

  Recruiting at 3 sites Universiteit Antwerpen · Edegem and 2 other locations · NCT07770126

• Endoscopic screening for H. pylori, intestinal metaplasia, and Barrett's mucosa during screening colonoscopy

  This project will try adding a gastroscopy with biopsies to routine screening colonoscopy to see how often H. pylori and early stomach changes appear in adults without upper GI symptoms.

  Recruiting Sigmund Freud PrivatUniversitat · Vienna · NCT07346521

• Disitamab vedotin plus trastuzumab and tislelizumab versus chemotherapy plus trastuzumab (± pembrolizumab) for HER2‑high advanced gastric or gastroesophageal junction adenocarcinoma

  This trial tests whether combining disitamab vedotin with trastuzumab and the immunotherapy tislelizumab works better than standard chemotherapy with trastuzumab (with or without pembrolizumab) as first‑line treatment for people with HER2‑high advanced gastric or gastroesophageal junction cancer.

  Recruiting Phase 3 RemeGen Co., Ltd. · Beijing, BJ-Beijing · NCT07315750

• Using the PAGODA algorithm to guide FOLFOX dose changes and reduce unplanned chemotherapy delays

  This trial will test whether using the PAGODA algorithm to guide dose changes during FOLFOX chemotherapy for people with gastrointestinal cancers can reduce unplanned treatment delays.

  Recruiting at 391 sites Alliance for Clinical Trials in Oncology · Fairbanks, Alaska and 397 other locations · NCT07283939

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.